Ph Health
As of the edition of 20 October 2026, Ph Health runs 16 drugs, 16 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 16 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ketamine | none listed | 10 |
| Oxytocin | none listed | 1 |
| Epinephrine | none listed | 23 |
| Estradiol | Ends 2032 (patent) | 6 |
| Cyanocobalamin | none listed | 0 |
| Vasopressin | none listed | 0 |
| Nalbuphine | none listed | 1 |
| Ephedrine | none listed | 9 |
| Micafungin | none listed | 0 |
| Estradiol valerate | none listed | 0 |
| Liothyronine | none listed | 2 |
| Colistimethate | none listed | 0 |
| Dantrolene | none listed | 2 |
| Propylthiouracil | none listed | 0 |
| Trimethobenzamide | none listed | 0 |
| Methohexital | none listed | 0 |
A route B row is one company at one target.